20-year survival expected for four out of five children who receive liver transplants
April 14, 2016
Press Releases
Liver transplantation has become a common treatment of liver disease over the past thirty years; however long-term patient outcome data has been scarce
April 14, 2016, Barcelona, Spain: A new study presented today shows that 20-year survival after childhood liver transplantation can be expected for almost 80% of patients. The study, presented at The International Liver CongressTM 2016 in Barcelona, Spain, shares long-term outcome data from medical records of children who received liver transplants over a five-year period, with a mean follow-up of 22 years.
Pediatric patients currently account for approximately 12.5% of liver transplant recipients1 and in Europe approximately 6,973 people received a liver transplant in 2012.2
“Until now there has been no good answer as to how long children could be expected to live after liver transplantation,” said Josefina Martinelli, Paediatric Liver Unit, AP-HP and lead author of the study. “While each child receiving a transplant is unique and every procedure is different, this study provides robust evidence on the average expected survival rates, an important consideration for the parents of children who undergo this complicated procedure.”
The authors retrospectively analysed the medical records of 128 consecutive children who underwent cadaveric transplantation (whole liver n=47, partial n=77, split n=4) in BicĂȘtre Hospital, France from 1988 to 1993 at a median age of 2.5 years.
According to the study, patient survival rates recorded at five, 10, 15 and 20 years were 84%, 82%, 80% and 79%, while graft survival rates were 73%, 72%, 67% and 65% respectively. The most common complications experienced by patients were infection (59%), followed by acute (44%) and chronic (37%) rejection. Chronic kidney disease stage 2 or more was present in one third of patients. A total of 100 patients survived 20 years or more after transplantation.
“This study is evidence of the great progress the medical community is making as we continue to learn more about how the body deals with transplanted organs,” says Professor Laurent Castera, EASL Secretary General.
This blog is all about current FDA approved drugs to treat the hepatitis C virus (HCV) with a focus on treating HCV according to genotype, using information extracted from peer-reviewed journals, liver meetings/conferences, and interactive learning activities.
Risk Of Developing Liver Cancer After HCV Treatment
- Home
- Newly Diagnosed With Hep C? Or Considering Treatment?
- All FDA Approved Drugs To Treat Hepatitis C
- Hepatitis C Genotypes and Treatment
- Mavyret (glecaprevir/pibrentasvir)
- Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)
- Epclusa® (Sofosbuvir/Velpatasvir)
- Harvoni® (Ledipasvir/Sofosbuvir)
- VIEKIRA XR/VIEKIRA Pak
- Zepatier(Elbasvir/Grazoprevir)
- Cure - Achieving sustained virologic response (SVR) in hepatitis C
- HCV Liver Fibrosis
- FibroScan® Understanding The Results
- HCV Cirrhosis
- Staging Cirrhosis
- HCV Liver Cancer
- Risk Of Developing Liver Cancer After HCV Treatment
- Treating Elderly HCV Patients
- Fatty Liver Disease: NAFLD/NASH
- Current research articles on ailments that may be related to HCV
- Is There A Natural Way To Improve Liver Fibrosis?
- Can Food Or Herbs Interact With Conventional Medical Treatments?
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment